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ABSTRACT
Depot medroxyprogesterone acetate (DMPA) is a long
acting progesterone only contraceptive agent. Side
effects such as irregular bleeding patterns and weight
gain are attributed to discontinuation.
The purpose of this study was to describe depot
medroxyprogesterone acetate discontinuation after weight
gain in 17 to 19 year-old adolescent girls.
A retrospective review of 26 medical records was
conducted. Descriptive data reflected a mean subject age
of 17.12, predominately, white (88.5%) with Hispanic
ethnicity (69.2%). The average weight change at the
second injection was -.65 pounds, and at the third, 1.41
pounds. At the third injection a 15.38% (n = 4) method
discontinuation rate was noted. Cumulative weight gain
over six-months was .61 pounds.
Although a three-pound or greater weight gain was
noted in seven girls in three months, only one chose to
discontinue. This study did not provide evidence to
support weight gain associated with discontinuation. Data
suggests that although weight gain may be experienced,
girls in this setting maintain adherence to this
effective method at least up to six months.
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CHAPTER ONE ,
'INTRODUCTION
Background
Teenage pregnancy prevention continues to be a high
priority public health issue. Four out of ten adolescent
girls become pregnant at least once before age 20, that
accounts for about one million pregnancies per year in
the United States alone (Curtain & Martin, 2000). Finding
effective ways of dealing with the problem is of concern
to parents, schools, public health departments, and
politicians across the nation (Satcher, 1999). The scope
and issue of high-risk behaviors such as early sexual
involvement is multi-faceted and includes teen pregnancy
prevention, sexually transmitted disease (STD) and HIV
prevention, and teen parenting education, all of which
have implications for society at large (Kann, Kinchen,
Williams, & Ross, 1998).
According to Jay, DuRant and Lift (1989), education
combined with access to family planning services is
imperative when dealing with pregnancy prevention.
Recognizing -the need for contraception and making it
1
available to adolescent girls is very important, but so
is the follow up and method adherence.
Statement of the Problem
Depot medroxyprogesterone acetate [DMPA] (Pharmacia
& Upjohn Company, 1995) is a progesterone-only hormonal
injection. DMPA is given intramuscularly every three
months to suppress ovulation. The 150 mg DMPA injection
is administered within the first five days after the
onset of menses.- At that time follicle-stimulating
hormone and luteinizing hormone are lower in the plasma,
resulting in inhibition of ovulation (Archer, Irwin,
Jensen, Johnson, & Rorie, 1997). When the DMPA
contraceptive regimen is followed correctly a very low
failure or pregnancy rate of 0.3-2.3% has been reported
(Branden, 1998) .
One significant problem with this method is the
individual contraceptors compliance. Returning for
follow-up injections and side effects are the most common
reasons for method discontinuation (Lim, Rieder, Coupey,
& Bijur, 1999) .
Physical and psychological side effects to depot
medroxyprogesterone acetate (DMPA) include weight gain,
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irregular menstrual bleeding, amenorrhea, headache,
nervousness, abdominal cramps, dizziness, bloating,
swelling of the hands and feet, backache, depression,
insomnia, acne, breast tenderness, facial hair and hair
loss (Sangi-Haghpeykar, Poindexter, Bateman, & Ditmore,
1996; Pharmacia & Upjohn, 1995). The side effects most
disturbing to adolescents are menstrual irregularities
and weight gain (Lim et al., 1999; Matson, Henderson, &
McGrath, 1997; Harel, Biro, Kollar, & Rauh, 1996).
Normal physical and sexual maturation described by
Tanner (1962) varies in girls. Estrogen and Progesterone
not only affect sexual development but aide in the
completion of bone growth.
Zacharias and Rand (1983) reported on the rapid
height and weight changes that occur during puberty over
a two to three year period. The peak height velocity
occurs at 11.63 years of age and culminates at 13.1 years
of age in American girls. At the peak of growth, which
generally occurs in the year before menarche girls can
grow three to five inches. In the United States'menarche
occurs on average at age 12.5, about 2 to 2.5 years after
the first breast changes appear. A girl is about 90
percent of her final height at menarche. By 14 or 15
3
years of age (Tanner, 1985), or two years after menarche,
most girls have reached final adult height (see Appendix
A). These girls usually gain from 10 to 15 pounds in the
five years following menarche. By age 17 most adolescent
girls in the United States have reached their final
height and weight has stabilized.
Weight gain is an important concern to adolescent
girls and contributes significantly to their decision to
continue or choose another contraceptive method (Davis,
1996). Among adolescent girls approximately half reported
discontinuing the method secondary to weight gain (Harel,
Biro, & Kollar, 1995). Davis (1996) states it is unclear
exactly why weight gain occurs but it may be due in part
to DMPA accumulation stimulating the appetite, in
addition to decreased physical activity, increase caloric
intake, and slowing of the metabolic rate.
Purpose of the Study
The purpose of this study was to describe depot
medroxyprogesterone acetate discontinuation after weight
gain in 17 to 19 year-old adolescent girls.
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Theoretical Framework
Theorists have conceptualized growth and development
as a series of tasks that must be accomplished in order
to transition from one stage to another. In a
developmental theoretical model developed by Erikson
(1968), the fifth stage is the adolescent stage (12-19
years of age), in which moral development occurs:
Identity vs. role confusion. To successfully transition
to the next stage the adolescent must develop an
individual identity. The rapid, marked physical changes,
preoccupation with appearance and need to integrate
personal values with those of society must be achieved to
attain a positive identity. Without positive identity
achievement, low self-esteem may occur.
According to Mendelson, Mendelson, and Andrews
(2000), body-esteem or appearance is an essential part of
a person's identity or self-esteem, appearance is always
immediately apparent to others. Preoccupation with
physical appearance and physique is of greater concern to
adolescent girls than any other age group (Bruch, 1981).
Body esteem refers to the self-evaluation of one's
body or appearance and. is the only self-esteem domain
that has been studied extensively in overweight
5-
individuals (Mendelson et al. , 2000) . Mendelson,
Mendelson and White (1996) revealed age' and gender
modified weight-related deficits in self-esteem.
Overweight adolescents were apt to have relatively low
self-esteem. Being overweight also was found to affect
girls in later adolescence, in contrast to early
adolescence in boys. Martin, Housley, McCoy, Greenhouse,
Stigger, Kenny, Shoffner, et al. (1988) support the
conclusion that as weight increased self-esteem
decreased. Research has shown that a more negative body
image is related to lower self-esteem (Guinn, Semper,
Jorgensen, & Skaggs, 1997) .
Self-esteem and depression were studied by Kim and
Kim (2001), findings reveal that girls who perceived
their weight problem as more severe had lower self-esteem
and experienced greater depression than those who
perceived their weight problem as less severe. Thus, the
perception of a weight problem, in other words,
appearance, was meaningful in assessing self-esteem and
depression.
According to Neel, Jay and Lift (1985) adolescent
girls typically negotiate self-concept and autonomy at a
time when they are becoming sexually active. The unstable
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self-esteem during the adolescent years may be such that
decision making is impaired (Papalia & Olds, 1981) .. A
review of literature by Crockenberg and Soby (1989) on
self-esteem and contraceptive use indicated that multiple
studies have shown an association between poor
contraceptive use and low self-esteem, and that no study
they found showed low self-esteem related to proper use
of contraceptives.
Contraception refers to a wide range 'of methods
developed to prevent pregnancy. Methods available to the
potential contraceptors range from barrier to hormonal
methods. Pregnancy prevention is a personal choice and
the girl must evaluate her own ability to adhere to the
chosen method for success.
According to Jay, et al. (1989) contraceptive
behavior has four components. The first component is the
adolescent girls decision to use contraception. This
decision, based on fear of pregnancy, motivates her to
seek contraception. The second component is choice of
contraceptive method. To choose a method the girl seeks
information, is provided with education on action,
efficacies, required follow up, and side effects of the
method. Although verbal instruction and written materials
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are provided regarding benefits and barriers to methods,
the full impact of potential side effects may not be
fully understood until the girl experiences them herself.
The third component is contraceptive compliance.
Contraceptive compliance can be defined as a regular
pattern of adherence by using the method in a consistent
and ongoing way to prevent pregnancy (Jay, Lift, &
DuRant, 1984). Contraceptive compliance is essential for
method success (Braden, 1998). However, concern over
appearance may be so strong that a decision could be made
to discontinue the use of contraception and risk
pregnancy, despite the methods effectiveness in pregnancy
prevention (Neel, et al., 1985). The fourth, and final,
component is a decision to change methods or discontinue
use. At this stage the girl may recognize physical or
psychological side effects of the contraceptive method
and choose to discontinue use or change methods.
Theory Application
An existing theory that addressed contraceptive
discontinuance in adolescent girls was not identified.
The theoretical framework used in this study integrated
the components of contraceptive use and compliance as
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determined by Jay, et al. (1989) and body-esteem research
conducted by Mendelson, et al. (2000). By integrating the
concepts we were able to describe and explain
contraceptive adherence.
This framework describes the linear process by which
a girl chooses to initiate DMPA as a contraceptive
method, confronts the side effect of weight gain,
interprets the weight gain through body-esteem, and then
makes a choice to discontinue the method.
The most important component in this theory
affecting the continuance of contraception is low
body-esteem. It is reasonable to assume that if low
body-esteem is associated with weight gain and
appearance, and if that body change is associated with a
contraceptive choice, the girl will rethink her options
and will choose to discontinue the method (Jay, et al,
1989) .
Figure 1. Low Body Esteem as a Mediating Variable for the
Discontinuance of Depot Medroxyprogesterone Acetate After
Weight Gain in Adolescent Girls
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Limitations of the Study
Study limitations included a convenience sample of
students attending one of three school-based clinics.
Thus, results could not be generalized to the overall
population of adolescents. Data collection was performed
as a retrospective chart review. Thus, some records may
have had incomplete charting and did not provide all the
detail required to be included in the study. Due to
constraints by the California Education Code on surveys
of students regarding sexual behavior and attitudes, and
the fact that the clinical sites protect student
confidentiality, a prospective study in this case would
have been difficult to complete. Because the study was
conducted at school-based clinics with vigilant school
nurses, discontinuation due to missed appointments was
lower than expected since accessibility was not an issue
thus, discontinuation should not be compared with other
community based clinic studies.
Definition of Terms
An adolescent girl was defined as a girl age 17-19 years
of age.
10
Weight gain was defined as pounds over baseline weight,
which was measured on calibrated weight scales, at
the initial DMPA injection.
Discontinuation of DMPA was defined as girls who did not
return for a follow-up injection after 104 days, or
those who stopped use and either chose another
method or used no contraceptive method.
Depot medroxyprogesterone acetate is a highly effective
progesterone only long-term injectable hormonal
contraceptive agent that is administered
intramuscularly every three months.
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CHAPTER TWO
REVIEW OF THE LITERATURE
One of the goals of Healthy People 2000 was reducing
pregnancy among girls age 15-19 to no more than 50
pregnancies per 1,000 adolescents. In 1998, the live
birth rate for girls age 15-19 was calculated to be 51.1
per 1,000. When live birth rates are added to information
regarding abortions and fetal loss, the pregnancy rate in
1996 was estimated -to be' 98.7 pregnancies per 1,000
women. This total pregnancy estimate was' down 15% from a
high of 116.4 in 1991 (CDC, 2000).. The State of
California reported pregnancies for the same period and
age group at 98 pregnancies per 1,000 in 1998. Reducing
overall pregnancy rates continues to be a goal for the
future. The objectives for Healthy People 2010 continue
to target the teen pregnancy rate and set the goal at 43
pregnancies per 1,000 females age 15-17.
Strategies used in the effort against teen pregnancy
include sex education in public schools, community
efforts, support groups, and increased availability of
contraceptive methods through confidential primary care
and clinic providers. At this time a variety of
12
contraceptive methods are available ranging from barrier
methods to hormonal methods. Hormonal methods are
increasingly popular with the adolescent women who seek
family planning services. All contraceptive methods have
their own set of side effects, contraindications,
effectiveness ratings, barriers to use, failure rates and
benefits. Hormonal therapy, including daily oral
contraceptives and long-term hormonal therapy, is popular
with young women because of the effectiveness.
Effectiveness of each therapy is dependent on a regular
regimen of compliance with the method.
Contraceptive Use in the United 
States by Adolescents
Oral contraceptives and condoms are the most
commonly used methods by adolescent girls in the United
States; however, compliance is known to be poor.
Middleman, Robertson, DuRant, Chiou and Emans (1997)
conducted a study on contraceptive methods used by
sexually active teens. Study subjects (N = 943) came from
a school-based clinic and hospital based adolescent care
clinic. Subjects were given a questionnaire to gather
data. Findings included oral contraceptive use in 39
percent, DMPA or Levonorgestrel in 5.4 percent, and no
13
hormonal therapy in 55.6 percent. Other studies also
support the popularity of oral contraceptives. Oral
contraceptives are highly effective when taken properly.
The problem with a method requiring daily compliance is
that adolescents are noted to be poor at remembering the
regimen. This data is reflected by the fact that
"pregnancy rates for teens using oral contraceptives are
almost double the rate experienced in adult women"
(Davis, 1996, p.408). To reduce the overall pregnancy
rates, condoms, spermicides and long-term hormonal
methods including levonorgestrel (Norplant) and depot
medroxyprogesterone acetate (Depo-Provera) appears to be
effective and appropriate methods for teens.
Depot medroxyprogesterone acetate, while used
worldwide for over 25 years, was not approved for use in
the United States until 1992. DMPA is an injectable
progesterone contraceptive that is administered
intramuscularly every 12 weeks. Compliance with this
method requires the user to return to her provider every
3 months (10-13 weeks) for DMPA administration. Because
of the three-month intervals between injections,
compliance would naturally seem to be easier, and thus be
a very desirable method for teens. One study on DMPA use
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indicates 30% of users were younger than 21 years of age,
and three-quarters were unmarried (Sangi-Haghpehkar et
al., 1996) .
Continuation of Depot 
Medroxyprogesterone
Acetate Use
Despite the effectiveness and ease of compliance
with DMPA, its use continues to be a significant problem.
Barriers to compliance in teens may include
confidentiality issues, health care access, missed
appointments, and lack of education on the method
including possible side effects at the time of first
injection. A family planning clinic in the midwest
conducted a study to determine continuation with DMPA use
(Westfall, & Main, 1996). Clinic clients were categorized
as discontinuing if they did not return for a follow-up
injection after 105 days. Results indicated that of the
5,178 women who initiated the method, only 57% returned
for the second injection. Over the course of a year, only
23% continued DMPA therapy and received four injections
in one year. This result is in stark contrast to
continuation rates for other contraceptive methods, such
as oral contraceptives, with rates from 70-90% compliance
15
over the course of one-year (Westfall, & Main, 1996) .
Researchers (Lim et al., 1999) studied-the DMPA
continuation rates and characteristics of long-term users
in minority inner-city adolescents. The study showed DMPA
continuation rates to be 70.3% at six months, 48.3% at
nine months, 31.5% at 12 months, and 12.8% at 24 months.
This accounts for about one third of those initiating the
method continuing at one year. A missed appointment was
the most common reason for discontinuation of DMPA
(41.7%) . Of the 156 adolescents who discontinued DMPA use
40% restarted the method later. Reasons for discontinuing
DMPA included irregular bleeding patterns at 17.3%,
followed by weight gain at 14%.
Polaneczky & Liblanc (1998) studied compliance and
reasons for discontinuing the method. Record reviews and
telephone interviews were conducted to gather data on
DMPA users over a three-year period at two New York City
clinics. The 159 females had a mean age of 17.7 (+/- 1.5)
years, and a median of one pregnancy. Continuation rates
for DMPA at three months was 71%, 48% at six months, and
27% at 12 months. Of those who discontinued use, 37%
restarted the method with a mean time of 8.4 months after
discontinuation. Menstrual irregularities (26%) were
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cited as the primary reason for discontinuing followed by
weight gain (18%). Although continuation statistics were
low, of those who quit over a third restarted the method.
Weight Gain Associated With Depot 
Medroxyprogesterone Acetate Use
Side effects that cause the greatest concern for
teens are menstrual irregularities, weight gain,
headaches, and hair loss. Teens are particularly
conscious of changes in their bodies. Weight gain is
particularly disturbing to the group., as it is noticeable
to themselves and others. The benefit-of DMPA as a safe
and effective contraceptive method'is many times
overlooked when weight gain is associated with hormonal
therapy by the potential new contraceptive user. It
remains unclear if DMPA causes weight gain in adolescent
teens. The weight gain experienced by some teens may be
associated with decreased physical activity, eating
habits, slowing of the metabolic rate and increasing
caloric intake rather than DMPA use itself.
Weight gain associated with DMPA use may be a result
of a variety of factors however perception does influence
a decision to use the method. Weight gain beliefs about
DMPA among three groups of contraceptors, including oral
17
contraceptive users, DMPA, and Levonorgestrel users vary
However, after receiving education over half the
responders in one study indicated they believed DMPA
would cause menstrual irregularities and weight gain
(Cushman, Kalmuss, Davidson, Heartwell, & Rulin, 1996).
Research on weight gain associated with DMPA use is
mixed. Contradictory evidence is available to support no
weight gain in women resulting from DMPA use. In a study
comparing DMPA, oral contraceptives, and Levonorgestrel
conducted by Moore, Valuck, McDougall, and Fink (1995),
results differ from much of the research conducted on
weight gain. Fifty women age 15-30 were represented for
each of the three treatment groups. The mean weight gain
after one year was as follows -0.93 kg (95% CI = -1.3 to
-0.5) in the oral contraceptive group, -0.81 kg (95%
CI = -1.6 to 0.1kg) in the Norplant implant group, and
+0.06 kg (95% CI = -0.4 to 0.6kg) in the Depo-Provera
contraceptive injection group. The weight gain in each
group was either negative or not significantly different
from zero.
Other reasons aside, many teens associate real or
perceived weight gain with the use of DMPA itself. In a
Study conducted by Harel, et al. (1995) on effects of an
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early second injection, half of all teens that
discontinued DMPA reported doing so because of weight
gain or increased appetite. The body mass index (BMI)
increase experienced by the adolescents on a regular DMPA
schedule showed an increase of 0.40+0.14 in their BMI
as compared to the baseline. Girls who received an early
second injection had a greater change in BMI of 0.99 +
0.22. The girls themselves perceived the change with 70%
of the early injection group reporting increased appetite
and weight gain, compared to 39% of the regular scheduled
group. In 1973, Schwallie and Assenzo studied the weight
changes in 3,857 women in one of the largest studies
conducted on DMPA in the United States. These women
represented 72,215 women-months of experience. All
received DMPA every 90 days. Progressive weight gain was
noted with an average of five pounds by 12 months, 8.1
pounds by 24 months and 13.8 pounds by 48 months. This
progressive weight gain was the reason 66 women (1.7%)
gave for discontinuing the therapy.
Reasons for discontinuation of DMPA are consistent
with findings in a study conducted by Harel, et al.
(1996) . Again, the study of 35 adolescents revealed
irregular menstrual bleeding in 21 (60%), weight gain in
19
14 (40%), and increased headaches in 9 (26%). The
increased BMI found at discontinuation of DMPA showed an
increase of 1.1 + 0.2 in their BMI that persisted up to
six months after discontinuation. Risser, Gefter,
Barrett, and Risser (1999) compared adolescents in two
hormonal contraceptive groups. The two groups were
comparable except the DMPA users (n = 44) had a greater
mean BMI than the oral contraceptive (OC) users (n = 8 6
Mean and median weight gains in one year were 3 . 0 (4.5)
and 2.4kg in the DMPA users and 1.3 (3.9) and 1 .5kg in
the OC users. Of adolescents using hormonal
contraceptives, weight loss or weight gain of less than
five percent was noted in 56% of DMPA users and 70% in
oral contraceptive users. Excessive weight gain, which
was defined as weight gain greater than 10% of baseline
weight, was measured in 25% of DMPA users and seven
percent of OC users. The significant findings that
adolescents who gained less than five percent of their
baseline, weight at three months, 14 (93%) gained even
more weight at 12 months. DMPA users were more likely
than OC users to gain less than 10% of their baseline
body weights. In another study, a cohort of 172 Navajo
women in New Mexico was' studied over a' two-year period to
2 0
determine weight gain. At one year, a mean weight gain of
six pounds was documented. At the end of the second year
an 11-pound weight gain was observed (Espey, Steinhart,
Ogburn, & Qualls, 2000).
According to Harel, et al. (1996), a trend toward
BMI increase in adolescents has been noted. Findings
indicate that the increase in BMI may persist up to six
months after discontinuation of the therapy. The
researchers indicate that although reasons for weight
gain in adolescents using DMPA may be unclear, it may be
that progestins, particularly DMPA, can accumulate in
preoptic and hypothalamic neurons, and directly stimulate
hunger centers at brain level. If the hunger centers in
the brain are stimulated this would support the
hypothesis that the weight gain may be from caloric
intake associated with poor eating habits.
Summary of Literature Review
■ The literature reflects mixed results. Research on
compliance with DMPA use indicated that only about
one-third of those who initiate the method continue up to
one year. This rate is due in part to missed provider
visits and side effects. Side effects of greatest concern
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to users include irregular bleeding patterns and weight
gain. Although not all research indicates weight gain
associated with DMPA, the majority of studies reviewed
indicate a positive association between these two
factors. Moreover, teenagers do associate weight gain
with DMPA use. To boost adherence to this long-term
hormonal method it is important to continue the study on
the association between these variables.
Hypotheses
There will be a significant' increase in
contraceptive discontinuation for 17-19-' year old girls
who use depot medroxyprogesterone acetate if they
experience a three-pound weight gain in 3 months.
22
CHAPTER THREE
METHODOLOGY
Introduction
This study used a descriptive retrospective chart
review to examine weight gain and depot
medroxyprogesterone acetate use. Medical record visits
were reviewed at three-month injections.
Subj ects
The convenience sample for this study was composed
of adolescent girls age 17-19 that initiated DMPA as a
contraceptive method at one of three high school-based
clinics. Data was obtained through a retrospective chart
review from September 1999 through June 2001. Girls were
excluded from the study if they: 1) had delivered a baby
in the last 12 months; 2) left school for any reason; and
3) any girl with a medical condition that would
contribute to abnormal weight gain or loss. The medical
records contained confidential information on overall
health, vital signs, height and weight, parity, current
and previous contraceptive use', .history of sexually
transmitted infections and subsequent treatment,
morbidity reports, a variety of lab work including urine
23
analysis, hemoglobin, urine pregnancy test results,
results from STD testing, Pap smears, wet mounts,
detailed history of sexual activity, psychosocial factors
and history of high risk behaviors such as same sex
partners, drug and alcohol use, and contraceptive
behaviors.
For the purposes of this study, the length of DMPA
use was calculated at weekly intervals. Method
continuation was calculated from start to stop dates. The
start date was defined as the date of first injection.
The discontinuation date was the day the girl made a
choice to discontinue use or 104 days after the last
injection. The 104—day mark was used as a discontinuation
date because the manufacturer recommends a pregnancy test
after that time, before restarting the method. Height and
weight were measured using standard scales that were
calibrated and certified as accurate on a yearly basis.
Setting
This study was conducted at three high school based
health clinics. The clinics provided confidential
counseling, general medical care, immunizations, acute
24
care, dental services, and family planning services to
students enrolled at the schools.
The confidential services offered by the Fontana
Unified School District are provided respecting minor
consent laws for the State of California. Yearly Teen
Health Center Consent Forms (see Appendix B) are sent to
parents. The card provides accessibility to many health
care promotion and preventative services. After the
consent is signed by the parent or guardian, the student
if afforded confidentiality as is clearly noted on the
consent. If an adolescent chooses to access confidential
family planning or sexually transmitted disease care
through the school based clinics they are enrolled in the
Family Pact, State-Only Family Planning Program. As part
of the enrollment and eligibility certification process
the enrollee signs an application allowing data
collection for outcomes studies and program evaluation
purposes (see Appendix C).
The high schools are located in a metropolitan urban
area. The community is comprised of a primarily Hispanic
population that is reflected in the student population.
Socioeconomic status varies depending on which region of
the city a high school may be located. The largest high
25
school with a population of 3,800 students was located in
the lowest economic part of the city. Many students use
the health clinics as their primary provider as they are
uninsured or fall into the category of the working poor.
The clinics provide services to students across the
district. The clinics are staffed with registered nurses,
nurse practitioners and physicians who volunteer their
time to the schools. The services rendered are free to
the student under school district allotments, grants and
reimbursement for billed services.
Study Variables
Socio-demographic data was collected on all subjects
and included age in years, race (White, African American,
Asian American, or Other), ethnicity (Hispanic or not),
parity, and previous contraceptive use answered as "yes"
or "no". Data collected at first visit and/or subsequent
visits to assess weight change and DMPA use included
height, weight, DMPA compliance in a timely manner and
reason for method discontinuation if available.
Procedure
After obtaining written approval- from the
Comprehensive Health Department of the Fontana Unified
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School District (see Appendix D), and approval from the
California State University at San Bernardino
Institutional Review Board (see Appendix E) data
collection was initiated. Records were gathered and kept
in a secure file cabinet housed in a locked records room.
Data collection was done when no students or other staff
were in the room to guard confidentiality. A standard
chart-audit tool was used to collect data (see Appendix
F). The data collection tool was pilot tested by two
researchers on five medical records to determine
interrater reliability and establish tool validity prior
to data collection. Each medical record was pulled and if
it met inclusion criteria, data was' extracted
individually. The data collection tools were numbered but
contained no medical record number or any other
information which could identify the subjects.
Records were reviewed for follow-up injections every
10-14 weeks. At follow-up visits, weight and any reported
side effects were recorded. Method discontinuation was
also recorded, including reason if indicated, and what
contraceptive method was chosen to use following
discontinuation.
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CHAPTER FOUR
RESULTS AND DISCUSSION
Data Analysis
Data collected included demographics and data that
described weight gain and discontinuation of DMPA. The
convenience sample for this study was composed of
adolescent girls age 17-19 who initiated DMPA as a
contraceptive method at one of three high school-based
clinics. Girls were excluded from the study if they: 1)
had delivered a baby in the last 12 months; 2) left
school for any reason before the second or third
injection was scheduled; and 3) any girl with a medical
condition that would contribute to abnormal weight gain
or loss
Socio-demographic data was collected on all
subjects. At the time of DMPA initiation, age in years
was reported as a mean and standard deviation. Nominal
data included race (White, African American, Asian
American, or other) and was reported as a percentage.
Through the data collection ethnicity was; determined,
Hispanic and not Hispanic and reported as a' percentage.
Percentage was used to measure parity. Data collected at
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the first and subsequent visits reflected DMPA use and
follow up. Nominal data on method discontinuation was
collected as "yes" or "no" and reported as a percentage.
The Chi-Square test analyzes nominal data. It is
used to determine significant differences between
measured observed frequencies within the collected data
and expected frequencies. The data collected tested the
null hypothesis, that there is no significant difference
in the number of girls who continue and discontinue DMPA
use after weight gain. The Chi-square statistical test is
designed to test group independence or relatedness and
approximation. To adequately present the approximation,
the total number of medical records was be greater than
20. A limitation for this test is that if differences in
frequencies exist the analysis will not identify where in
the data the differences occur.
Data was entered and analyzed using computer
software SPSS 7.5 for Windows SPSS Inc, Chicago, IL.
Presentation of Findings
Collected and analyzed demographic data from 26
medical records provided overall information regarding
the subjects. The medical records reviewed met the
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inclusion criteria of 17-19 year old girls with an
average age of 17.12 (SD = .33). Race distribution
reflected the population as white 88.5% (n = 23), African
American 3.8% (n = 1), Asian American 3.8% (n = 1), and
other 3.8% (n = 1). Hispanic ethnicity was noted at 69.2%
(n = 18). Parity remained consistent with no history of
pregnancies reported (see Appendix G).
Baseline height for the study subjects ranged from
54 to 68 inches with a mean of 63.68 inches (SD = 3.04) .
Weight reflected a significant spread ranging from 102 to
240 pounds, with a mean of 146.63 pounds and the median
of 143.50 (SD = 36.27). Three subjects initiated the
study with baseline weights greater than 210 pounds (see
Appendix H). A decision was made to include all data
gathered due to limited population size.
This research study hypothesized that there would be
a significant increase in contraceptive discontinuation
for 17-19 year old girls who used DMPA if they experience
a three-pound weight gain in three months. The data
collected indicated that of those who gained greater than
three pounds in three months 87.5% (n = 7) continued with
DMPA use. The remaining 12.5% (n = 1) gained greater than
three pounds in three months and discontinued DMPA use.
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Of the 70.8% (n = 24) who continued with DMPA use
after the second injection 94.4% (n = 17), did not gain
greater than three-pounds in three months.
Table 1. Greater Than Three Pound Weight Gain in Three
Months and Depot Medroxyprogesterone Acetate
Discontinuation (Analysis Using Chi-Square)
Continue DMPA
at 3 Months
Total
Yes No
Weight Gain > 
In 3 Months
3 Pounds Count 7 1 8
(Yes) Expected
Count
7.4 0.6 8.0
Percent 87.5% 12.5% 100%
Weight Gain > 
In 3 Months
3 Pounds Count 17 1 18
(No) Expected
Count
16.6 1.4 18.0
Percent 94.4% 5.6% 100%
Total Count 24 2 26
Expected
Count
24.0 2.0 26.0
The Chi-square test performed did not provide
conclusive statistical evidence that DMPA discontinuation
would be significantly higher if greater than three
pounds were gained in three months (X2 = .376; p = .540) . 
Although there were no significant statistical findings,
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a trend toward method discontinuation was noted.
Percentages reveal a 12.5% discontinuation in girls who
experienced a greater than three pound weight gain
compared to 5.6% in those who did not gain weight.
On further analysis of data collected at the time of
the third injection, six month follow-up appointment, the
population subjects decreased to 22. These four subjects
who discontinued family planning services reflected a
15.38% (n = 4) discontinuation rate of DMPA use. One of
these four girls who discontinued services experienced a
three pound or greater weight gain at the second
injection 3.8% (n = 1).
The mean weight at the initiation of the study was
146.63 pounds (n = 26). At the second injection the mean
weight was noted at 145.98 pounds (n = 26), which was a
decrease of 0.65 pounds. At the time of the third
injection the mean weight was 145.11 pounds (n = 22),
with an overall weight gain of 1.41 pounds. The
cumulative weight change experienced by these girls was a
gain of 0.61 pounds.
32
CHAPTER FIVE
CONCLUSIONS AND RECOMMENDATIONS
Conclusions
This research study did not provide significant
evidence to support DMPA discontinuation when a
three-pound weight gain was experienced by 17-19 year old
adolescent girls. Although this was the study finding, it
is important to recognize that these girls did not
discontinue DMPA use despite weight gain at three months.
It was not possible to determine reasons for
discontinuation of service at the third injection.
However the overall population did not exhibit a
significant weight gain.
Recommendations
There are several significant limitations of the
findings in this research study. The sample size was
small and from a specific setting, thus limiting the
external validity of the results. With limited external
validity it is not possible to generalize the findings or
make conclusions outside of this study sample. Although
weight gain was not determined to have a significant
association with DMPA discontinuation there were other
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findings of importance. The data suggest that despite
weight gain, teens at school based clinics continued with
a very safe and effective contraceptive method for six
months.
In order to capture greater external validity, it is
recommended that a larger sample of adolescent girls in a
variety of settings be studied to determine the
relationship of characteristics such as age, educational
level and competence, socio-demographic status,
race/ethnicity, provider education and support, to method
adherence. By expanding the sample and collecting data
from a variety of settings, knowledge on weight gain
associated with DMPA discontinuation could be better
understood, leading to specific areas for educational
intervention.
In an effort to advance the practice of nursing it
is important to develop educational programs to address
the users understanding of the most common side effects
of DMPA administration to benefit their decision making
prior to initiating and during use of this contraceptive
method. Through education adolescent girls would then
have a better understanding and an enhanced ability to
monitor and control weight gain through dietary
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awareness, a regular pattern of exercise, and an overall
understanding of maturation and the metabolic cycle.
Body image perception is a significant area of
concern for adolescent girls that can effect overall
self-esteem. The theoretical framework developed for this
study predicted contraceptive discontinuation after
girls' experience weight gain that they relate as a side
effect to DMPA. In this setting girls did experience
weight gain however at three months only one girl
discontinued use. It would be beneficial to conduct a
study to define characteristics of girls and providers
that support management of side effects for contraceptive
method compliance. Effective target areas for support and
education may assist the girls in building and enhancing
body and self esteem. Through confidence they may learn
health-seeking behaviors that will benefit overall health
and wellbeing.
Further research should be conducted to not only
study the weight variability in populations of other
adolescent girls but also expand the length of the study
for up to two years to understand the potential or
probability of cumulative weight change. Through
increased information on weight gain and other side
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effects we may come to a better understanding of DMPA and
develop effective management strategies for the
adolescent population, thereby boosting overall adherence
to this effective contraceptive method and thus reduce
the overall teen pregnancy rate.
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APPENDIX A
BODY MASS INDEX
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2 to 20 years: Girls
Statufe^for-ege and Weight-for-age percentiles
NAME
RECORD#
12 13 14 15 16 17 18 19 20
0 F < F □ tt LU
10 11 12 13 14 15 16 17 18 19 20
& IU - O
 I F
'iRewsed and corrected November 28.2000.
SOURCE; Developed bythe National Center tor Health Stansncs in coUafioration swim
the National Center tor Chronic Disease Prevennon anci Heafth Promotion (2000).. 
httpdMvrw.edc.goij/gTOwtheharts
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2 to 20 years: Girls
Body mass index-for-age percentiles .
name - ■ feu.---- ---------------------------U- .
RECORD #________________
CDCSOUflCE; Developed by Wo National Center for Health Statistics in coSatwrauon with-ItfteNational CBntar(erChrontc.Disea^PfaVeriti6nand.HealWPrornofion'(2000). 
http^/www^c.gov/gro»rthchfi/t3
$
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APPENDIX B
TEEN HEALTH CENTER CONSENT
FORM
40
Fontana Unified School Distnet • .
TEEN HEALTH CENTER 
CONSENT FORM
The Teen Health Centers) will, have a physician and/or certified nurse practitioner available for comprehensive health services. These 
comprehensive services will address awide range of adolescent health problems and concerns' including but not limited to physical'exammations, oral 
.assessments/treatment foriroutme»illness/minor;injunes; health edusation. niitriticn, weight contrcl. smoking cessaticn, drug, and, alcohol referrals, 
prenatal and postnatal support, including birth control (which will be dispensed or provided by a. physician),and spots exams The center will 
encourage students to leam and develop skills related torhealth iand wellness. The heelih center will provide confidentiality as mandated by California 
Stale law. [also give my permission for distnet peer err reltotransport mychild to the appropriate clinic fee such services. , . , ».
If yoti WishiyoUr son or daughterto receive physicianfcertified nursepractitionenservices'Of dentist/dental.hygiene services/ please sign, date? 
and return this fonn to your student’s school. - . .
has permission to be seen by a physicinrVnurse practitioner, or
LASTNAME:........... FIRSTNAME DATE OF BIRTH ■. - - ...........
denbst/dehtat hygiene for dental screening.-dental cleaning a'nd placement of dental sealants at the Teen Health Center:
This authorization shall remain in effect for the 13_____ -30 school year. This consent shall remairi in erteU.urifilireVokedby’youiinwriting and
delivered to the principal: , • . j.. /
YES .................... .................................. _____ NO ________________________________ ' ■
PARENT/GUARO1AN SIGNATURE DATE PARENT/GUARDIAN SIGNATURE , DATE'.
Allergies(if any)_________________ - — ............................... ....... - . ,_______ ■ _________ ____ ,__ :.......................
■ Chronic Medical illness (pest/present);_________________________________ ■ ■■■ ........ ■■ ■ -............. • ■ ■ • ■ -. ■
, Current Medication flf anvil . _______  . ................. ............................................ ......... .............. - ‘ ' •
Date of Last Tetanus'Shot_________________ ___________________________ ' - ,■ - - ........... ,
Otherlmpoitant Health History; _____________ ' __________ :___________ 1________
: FamilyDocton........ ■ ................ - ■____________ ___________ ___^Family Dentists______ ______ ,______. .. ............. ........
4199: .................. '
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APPENDIX C
HEALTH ACCESS PROGRAMS
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Kttnrotf Hutiun-SeMces Agency /Ue^xm^^orHe^'^eWtces
HEALTH ACCESS PROGRAMS ^GGiviGilCRehllldeniificalionhiimb^.
FAMILY PACT PROGRAM"
CLIENT ELIGIBILITY CERTIFICATION (CEC)
This farmIsthe proparty'of thB'Stata'6t:Caliromla, Department of Health Services, Ofiteo et'Fatmly^lannlng. and cannotbechangeclorialtercik
Please' print answers to all questions. The queslions';about ;your .family size; inconre,,:and health-care insurance-afe to 
determine if you are eligible'for Family PACT Program services. , 2
• Providers must keep a copy, of this form in the client's medical record (See PPB1, Client Eligibility Certification Form 
Completion Section for code determinations.) , y' , ;j v .~>'G
Coda areas arc for Provider use only....   f. ...
Do.you currently receive Medi-Cal benefits or services? ■ ,; 
Do you have a Medi-Cal Benefits IdentificafionCard (B1C)?
BIC number Issue date \ *
* * . *
□ Yes
□ Yes
Do you have health care insurancefor family planning services? (Private insurance. Health, _□ Yes 
Maintenance>©rganizatipm(HMQ);iManaged,GareiPlan* Student Health insurance, etc;)
□ ;No-
□ No;
□ No
Do, we need to keep your family planning services confidential from your, partner, spouse, or □ Yes .DNo 
„ Confidentiality
Use 
hoir-catx
a * .... > >, , •-
ESstSiaifrez ' " : IMkfcfieirtaiwe:' Suffix (Jr. Sr.)
Is your current name the same as your name at birth? .If no, pnnt your name at birth,below. ‘ QYes □ No
Suffix <Jr.;Sr,)
■NurnheTofltve births County of residency Nrn&-d<pdZlPcodti ?
'Gender5.
□ Mala □ Female
• t 'Uf Social ceeunty.numbcr. 
, . cm • lr iGz-v
Mother's.firetnames. .... .
■Datg of; birth(mm/dd/yyyy)/
/ 1________
Piace'ofbsth (county, if,CaEfcrrua)
s y-CODr.
St^eififn^Califip^a)^.^., Coointty'{if.ncrtlJSA)';C
t cost
sZi-^
RaceZe'thriicity
1 n Asian • -2 □ Black 3 □ Filipino ”'4 □ Hispanic ~ ,.... .  —
5 □ Native American 6 □ Pacific-Islander j 7 □ White O'Q-Othfer - - ..... ..-...... ™
Primary Language
1 □ Armenian 2 □ Cantonese 3 □ English ' 4 □ Hmong S □ Khmer/Cambodian
6 □ Korean 7 □ Tagalog 8 □ Spanish 9 □ Vietnamese 0 □ Other
This information will be used to see if you>are enrolled in any state healths program. Information wilhalso be used to 
monitor health outcomes and, for program .evaluation purposes. -Your name-will not.be shared. Each individual has 
the right to revn w personal information maintained by .the provider unless exempt under Article 8 of the Information 
Practices Act. - . ‘
CornpSetaeligihflity (nformBtlon^oni'eversefSlcie^
,DHa446t'{8«3)^
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Elia hility Determination. Piease list all family members {self, spouse, and children) living in your household and supported by 
the family income List Ihe source of any earned or unearned income and the.amount ofincome, including income from 
employment, self-employment, tips, commissions, pensions, social security, child and/or, spousal support, ongoing insurance
Lame RthiJonJi pto Ycu Age
*X -* .* f K ,
t ' Source,ofJreccms
Ortas'- Kouth’y Inccm
(Ctoftxo tern ordcdueSdns.)„
(Self) > * - >.
‘ , > r ?
' i ■ > u
- - j / c <
„ j
Family size Total family income $ . ,, , ;
I declare under penalty of perjury that the information I have given on this form Is true, correct, and:complete; I 
understand that the giving of false information may make me ineligible for this program.
“Stgnature.(ortnarfc)ot8pplicanU | 'C&tei; : Sfgnature<tfwitnes£:to.marVorintefpfe!sf' ' 5' "" kOatej- ..... .....
- - ....... s ‘ r.
FOR PROVIDER USE ONLY
Providercerfificatton: □ Eligible for Family PACT Program
'□ Ineligible for Family PACT Program (Give applicant Fair,Hearing Rights.)
Medi-Cal .client eligible for Family PACT verified: Q Limited scope □ Unmet share-of-cost
Based upon the information provided, by the applicant and according to state-and federal requirements,. I certify that the 
applicant identified on this Client Eligibility Certification is eligible to receive family planning services under the Family PACT 
Program. If i neligible, the client has received a copy of this form which includes the Fair Hearing Rights.
Print nam? Signature ' ' Oats >
Annual Certification: If client is decertified (no longer eligible)
Date Reason code (see Pro wdof
MaraffiJ). -
Fair Hearing Rights
Any applicant for, or recipient of. services under the Family PACT Program has a right to a hearing conducted by the Department of Health 
Servicesregarding eligibility or receipt of services. An applicant or recipient does not have a right to contest changes made.to the eligibility 
stTid irrls cr herieti'; of the Family PACT Program.
First level review: If you wish to appeal either your denial’of,eligibility or receipt of services, please send'your name, telephone number, 
Eiildrc.se ard reason why you are requesting a review to the First Level Review address below. A request for a first level review must be 
ppslnnikeo Mllnn 20 working d ly. of Ihe denial of eligibility or services. The Office of, Family Planning may request additional Information by 
telephone or in wiilii q from the prawderoi trr .ppheant before,issuing a decision.
Fermi hCvtinj' You may appeal the dc.-.s,nn of ’hr first Irvrl review wilKu live working days of your receipt of the decision of the first level 
rc view ey cu ldini) your name, telephone num! er, aJdrc,j and rivisun for tile nppr ll lo the Formal Hearing address below At Ihe hearirq, 
vou mjy bi represented by a friend, relative La yei, or uUicr potion ot your che'ce A representative of Ihe prouder wr'l be pieseiil to 
oxo'Cin tie ri.as.onj for denying elqib.'rly. If you wont n rnlcrprolor provided al the heanng, please speedy Ihe l.irguage in your leti'-r 
requesting a heanng. ,,, , .
First Level Review
Oil co eFamirv Planning 
Department of Health Services 
‘ 714 P'Sheef Room 440,
P.0, Box 942732 
Sacramento, CA 94234-7320
Format Hearing
O’fice of Anminislrative He inngs and Appeals
Department of Health Services
714 P Street, Rr -m 1216
P.O.Box 942732
Sacramento, CA 94234-7320
DHS««1 ISO1)
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j Fontana Unified School District
9680 Citrus Avenue • P.O. Box 5090 • Fpntapa ■ CA 92334-5090 (909)357-5000 j
July 13,2001
;T(j:; Committce ontheft'otectionof Human Subjects 
GalifomiaStaterUniversity San Bernardino
Dear Sirs:
Please be advised that Donna Church -has, obtained permission to conduct her study of "Depot 
.Medroxyptogestcrpne Acetate Discontinuation After Weight train In 17 —19 Year Qld Adolescent Girls".. 
This retrospective chart review will consist of records fromstudents receiving health iscrvices in the 
Fontana Unified School District'dnring September? 1999 to’June2001..
... " Sincerely
Terry Paxton, RN, CPNP - 
Assistant Director 
ComprehensiveHealth'Services
>
A -
KARENJ.HARSHMAN.EdD. 
i Superintendent of Schools
(909)357 5000 ext 7010 Fax (909)357-5012
EMMANUEL) D'SOUZA
Associate Superintendent, Business Services
; (909) 357-5000 ext 7115' Fax (909)3575287
BOARD OF EDUCATION
" Kothy (Sinks 
Cur Hawthorn -
, Laura Abernathy Mancha
Rick McClure •_ ?
D Wayne Ruble.,EdD 
-Telecommunications Device 'o--the'[0eafj(909),357?5018
FRANCESCA.MA2ZOUNI I
Associate Superintendent Educational Services 
(909) 357-5000,ext. 7070- Fax (909)357+094
PATRICIAj.'P£OPLES,EdD, 
Associate-Superintendent. Human Resourced’
(909) 357-5000 ext. 7068 Fax" (909) 355-2O5S
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INSTITUTIONAL REVIEW BOARD
APPROVAL LETTER
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[ jAjF»F»R<Z>VEP
CALIFORNIA STATE UNIVERSITY 
SAN BERNARDINO:
Bull -Board Review 
IRBFile# 
01024 Thc'Califarnia
>State<&niv4rsity.
January 18,2002 cyxz-EP I
Ms. Donna Lea Church
Professor James E. Green ' •
Department of Education ■
California State University-
5500 Uni versity'Parkway i= •
San; Bernardino,’.California 92407 / •
- Dear Ms. Church:
Your application-to use human subjects, fitted,-“Depot Medroxyprogesterone’ Acetate 
Discontinuation Rates After Weight Gain in 17-19 Adolescent Girls”-has been-reviewed by the- 
Institutional Review Board (IRB). Your informed consent'statement should contain-a statement 
that reads, “This research has been reviewed' and approved by the Institutional Review Board-of 
CaliforniasState University, .San Bernardino.”
Please notify the IRB if any substantive changes are made in your research prospectus and/orany 
unanticipated risks to-subjects arise. If your project lasts longer than one year, you must reapply 
of approval af'the end of each year. You are required to keep copies of the informed, consent 
forms and :datafor<ab‘leasMhre&.-years.
If you have any questions regarding the IRB decision, please contact Michael Gillespie, IRB- 
Sccretary. Mr. Gillespie can be reached b'y phone at (909) 880-5027, by-fax at.(909) 880-7028, or 
by email at mgillesp.@csusb.edu. Please .include your application identification number (above) 
in’all correspondence.
Best of luck with your research.
Sincerely,.
Joseph Lovely Chair. 
Institutional Review Board
JI7mg' ■ - ’ - '• - . ;
cc: Professor-Ellen Daroszewski, Department of Nursing
550Q University?Park>vay, San:Bernardino,;GA924Q7-2397i
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RESEARCH STUDY DATA
COLLECTION TOOL
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Research Study Data Collection Tool
Data of Medical record Review: Code:
Age at Initial DMPA 
Injection:
Race:
1 = White
2 = African American
3 = Asian American
4 = Other
Ethnicity:
1 = Hispanic
2 = No Hispanic
Previous contraceptive 
use
1. Yes
2. No
Parity:
1. Pregnancies None
2. Abortions
3. Miscarriages
4. Live Births
Baseline Height (inches) 
and Weight (pounds) at 
DMPA initiation:
Date
Height
Height, Weight, and Side Effects
DMPA Initial Injection DMPA #2 DMPA #3
Date Date Date
Weight Weight Weight
Height Weight Change Weight Change
Comments Comments Comments
Weight gain > 3lbs
1. Yes 2. No
Continues 1. Yes 2. No
Weight gain > 3lbs
1. Yes 2. No
Continues 1. Yes 2. No
If students discontinues use at any time, reason for discontinuance:
Comments:
Reviewer:
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APPENDIX G
MEDICAL RECORD DEMOGRAPHIC
DATA
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Medical Record Demographic Data Summary
Demographic
Variables Demographic Data
Age 17 year olds 88.5%
18 year olds 11.5%
Mean Age 17.1154
Median Age 17.0000
Standard Deviation .3258
Race White 88.5%
African American 3.8%
Asian American 3.8%
Other 3.8%
Ethnicity Hispanic 69.2%
Non Hispanic 30.8%
Parity .None 100%
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APPENDIX H
SUMMARY OF WEIGHT STATIC
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Summary of Weight Status in Adolescent Girls Taking
Depot Medroxyprogesterone Acetate as a Contraceptive Agent
Data Label Mean Median Standard
Deviation
Baseline Weight at 
DMPA Injection
146.6346 143.5000 36.2760
Weight at #2 DMPA 
Injection
145.9808 141.5000 35.7062
Weight Change at #2 
DMPA Injection
-.6538 .0000 4.2586
Weight at #3 DMPA 
Injection
145.1136 139.0000 37.5246
Weight Change at #3 
DMPA Injection
1.4091 1.0000 4.7199
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